S&P 500 Healthcare Sector SPDR (XLV)

Despite recent underperformance relative to the healthcare sector, analysts remain fairly bullish on Intuitive Surgical's long-term fundamentals and growth potential.

Due to Pfizer’s underperformance relative to its peers over the past year, Wall Street analysts remain cautious about the stock’s prospects

Despite Amgen's outperformance relative to the healthcare sector over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.

AbbVie has underperformed the healthcare sector, and analysts remain somewhat optimistic about the stock’s outlook.

As UnitedHealth Group has considerably outperformed its sector peers recently, analysts remain highly optimistic about the stock’s prospects.

West Pharmaceutical Services has considerably outperformed the broader market over the past 52 weeks, and Wall Street analysts maintain a highly optimistic outlook about the stock’s prospects.

Waters Corporation has underperformed the broader market over the past year, but analysts are cautiously optimistic about the stock’s prospects.

Charles River Laboratories has underperformed the S&P 500 over the past 52 weeks, yet Wall Street analysts maintain a highly optimistic outlook about the stock’s prospects.

Regeneron Pharmaceuticals has underperformed the broader market over the past year, and analysts remain reasonably bullish about the stock’s long term prospects.

While Bio-Techne has lagged behind the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.